Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
81 studies found for:    "factor V Leiden thrombophilia" OR "Thrombophilia"
Show Display Options
Rank Status Study
21 Unknown  Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)
Condition: Cancer
Intervention:
22 Completed Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial
Condition: Deep Venous Thrombosis
Intervention:
23 Terminated Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)
Conditions: Venous Thromboembolism;   Fetal Death
Intervention: Other: Thrombophilia Testing
24 Completed Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies
Conditions: Pregnancy;   Iron Deficiency;   Iron Deficiency Anemia
Interventions: Dietary Supplement: Lattoglobina (Grunenthal) containing bLf;   Drug: FerroGrad by Abbott
25 Completed Does Vitamin D Deficiency Associated With Hypercoagulability & Increased Thrombin Generation?
Condition: Chest Pain
Intervention:
26 Completed Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome
Conditions: Venous Thrombosis;   Venous Insufficiency
Intervention:
27 Completed Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test
Conditions: Factor V Leiden;   Factor II;   Thrombosis
Intervention:
28 Recruiting Low Weight Heparin prOphylaxis for Placental‐Mediated Complications of PrEgnancy
Conditions: High Risk Pregnant Women;   Placental Insufficiency;   Preeclampsia
Intervention: Drug: Enoxaparin
29 Completed Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
Conditions: Acquired Antithrombin III Deficiency;   Coronary Artery Bypass
Intervention: Drug: Antithrombin III
30 Unknown  Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment
Condition: Disseminated Intravascular Coagulation
Intervention: Drug: ART-123
31 Terminated Safety and Efficacy Study To Compare Uniplas With Cryosupernatant Plasma In Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura (TTP)
Intervention: Drug: Uniplas
32 Not yet recruiting Octaplas Adult TTP Trial
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: Octaplas
33 Completed Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody;   Biological: Placebo
34 Terminated Thrombin Generation and Thromboelastography in Non-overt DIC
Conditions: Sepsis;   Disseminated Intravascular Coagulation
Intervention:
35 Terminated Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
Conditions: Thrombotic Microangiopathy;   Thrombotic Thrombocytopenic Purpura
Interventions: Drug: ARC 1779 Placebo;   Drug: ARC1779 Injection
36 Completed ADAMTS13 in Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention:
37 Terminated
Has Results
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Drug: Rituximab;   Procedure: Plasma exchange;   Drug: Corticosteroids
38 Withdrawn Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Condition: Purpura, Thrombotic Thrombocytopenic
Interventions: Drug: Octaplas infusion and placebo (group 1);   Drug: Octaplas infusion and placebo (group 2)
39 Completed Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
Condition: Protein C Deficiency
Intervention: Drug: Protein C Concentrate (Human) Vapor Heated
40 Recruiting Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
Condition: Antithrombin III Deficiency
Intervention: Drug: Plasma-derived AT-III concentrate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years